ANZLG HD3/TROG 99.01 - Hodgkins Disease IFRT - HD3 - TROG Cancer Research

TROG 2026 ASM: Early Bird Registration now open

Support our Km's for Cancer Research challenge today

$1.9 million grant sees TROG bring international trial to Australia

Apply now for Attendance Grants for our 2026 ASM

Submit your trial idea for our Concept Development Workshop before 2 November.

By w.paterson
14 August, 2021
0 Comments

An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Related Post

SUPREMO breast cancer trial results published in NEJM

6 November, 2025

SUPREMO trial findings signal change in breast cancer treatment

LATEST NEWS: 6 November 2025 Radiotherapy can be safely

23 October, 2025

TROG collaboration sees international skin cancer trial open in Australia

LATEST NEWS: 23 October 2025 TROG Cancer Research has